Stocks · Healthcare · Biotechnology
Armata Pharmaceuticals, Inc. ARMP
$3.52 +6.34% Close, Oct 2, 2026 · AMEX · Market cap $129.2M
Expensive vs sector
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -1233.6% from -514.4% a year earlier.
- The diluted share count rose 71.4% in a year.
- Revenue over the last four quarters was $3.3M, down 52.0% from a year earlier, slowing from -37.1% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth4Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 11%
- Revenue growth, 3-year CAGRBottom 17%
- Revenue growth accelerationBottom 14%
Quality52Neutral
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 27%
- Gross marginTop 45%
- Operating marginBottom 11%
- Accruals (lower is better)Top 1%
- Interest coverBottom 50%
Value9Very weak
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 2%
- Free-cash-flow yieldBottom 25%
- EBITDA / enterprise valueBottom 17%
- Sales / enterprise valueBottom 8%
Momentum25Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 21%
- 6-month returnBottom 2%
- 1-year return vs S&P 500Top 45%
- Distance from 52-week highBottom 4%
- Trend checklist (0–4)Bottom 14%
Revisions73Positive
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 10%
Stability40Weak
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 5%
- Maximum drawdown, 3 yearsBottom 36%
- Beta vs S&P 500 (lower is better)Top 13%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -37.1% | -52.0% | ↓ |
| Gross margin | 79.1% | 68.2% | ↓ |
| Operating margin | -514.4% | -1233.6% | ↓ |
| FCF margin | -467.3% | -781.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -52.0% | -37.1% | ↓ | Bottom 11% |
| Gross margin | 68.2% | 79.1% | ↓ | Top 45% |
| Operating margin | -1233.6% | -514.4% | ↓ | Bottom 11% |
| Net margin | -5825.3% | -374.3% | ↓ | — |
| Free-cash-flow margin | -781.9% | -467.3% | ↓ | — |
| Return on invested capital | -47.4% | — | Bottom 27% | |
| Revenue growth, 3-year CAGR | -3.8% | — | Bottom 17% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -185.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 173.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +68.8 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -3.26%
- Shareholder yield
- -3.26%
- Share count change, 1 year
- +71.4%
- Share count change, 3-year CAGR
- +19.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.6%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $15.00
- Target vs current price
- +326.1%
- Analysts with a rating
- 4
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +39.3% | +1.4% | +7.3% | +27.3% | — |
| May 13, 2026 | -731.6% | -2.0% | -6.0% | -16.0% | -47.7% |
| Mar 25, 2026 | -1700.0% | +4.9% | +24.7% | +69.4% | -13.8% |
| Nov 12, 2025 | -76.2% | -0.9% | +1.9% | -16.0% | +15.9% |
| Aug 12, 2025 | -15.4% | +4.2% | +10.6% | +25.0% | +105.1% |
| May 14, 2025 | +47.4% | -2.8% | +58.5% | +43.0% | +69.7% |
| Mar 20, 2025 | +34.3% | +1.0% | -17.1% | -40.7% | -6.0% |
| Nov 13, 2024 | +46.4% | -1.1% | -28.0% | -20.0% | -27.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.27 | -$0.45 | +39.3% | $2.5M |
| May 13, 2026 | -$3.16 | -$0.38 | -731.6% | $789,000 |
| Mar 25, 2026 | -$3.42 | -$0.19 | -1700.0% | $1.1M |
| Nov 12, 2025 | -$0.74 | -$0.42 | -76.2% | $1.2M |
| Aug 12, 2025 | -$0.45 | -$0.39 | -15.4% | $2.2M |
| May 14, 2025 | -$0.20 | -$0.38 | +47.4% | $491,000 |
| Mar 20, 2025 | -$0.23 | -$0.35 | +34.3% | $1.2M |
| Nov 13, 2024 | -$0.15 | -$0.28 | +46.4% | $3.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 127.08× | — | — | Bottom 8% |
| Free-cash-flow yield | -19.96% | — | — | Bottom 25% |
| Earnings yield | -215.63% | — | — | Bottom 2% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.8%
- 200-day average slope (20 days)
- -2.7%
- Distance from 50-day average
- -25.0%
- Distance from 200-day average
- -51.8%
- RSI (14)
- 35.8
- Relative volume
- 0.33×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 116.8%
- Volatility vs own 5-year history
- 78th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.42
- Correlation with S&P 500
- 0.06
- Current drawdown from 1-year high
- -76.2%
- Maximum drawdown, 3 years
- -78.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 10, 2021 | Apr 10, 2025 | -85.7% | 1046 days | 134 days (Oct 22, 2025) |
| Apr 21, 2026 | Oct 1, 2026 | -77.6% | 113 days | Not yet recovered |
| Nov 12, 2020 | Dec 15, 2020 | -32.7% | 22 days | 29 days (Jan 28, 2021) |
| Mar 10, 2026 | Mar 23, 2026 | -32.4% | 9 days | 11 days (Apr 8, 2026) |
| Oct 23, 2025 | Nov 3, 2025 | -32.0% | 7 days | 9 days (Nov 14, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $129.2M
- EPS, diluted (TTM)
- -$7.59
- Revenue (TTM)
- $3.3M
- 52-week range
- $2.94 – $16.34
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $4.5M | $5.5M | $4.5M | $5.2M | $4.9M |
| Gross profit | -$15.5M | -$29.5M | $3.6M | -$29.3M | $3.4M |
| Operating income | -$23.8M | -$36.9M | -$40.9M | -$42.4M | -$31.2M |
| Net income | -$23.2M | -$36.9M | -$69.0M | -$18.9M | -$173.8M |
| EPS (diluted) | -$0.96 | -$1.08 | -$1.91 | -$0.52 | -$4.80 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.2M | $491,000 | $2.2M | $0 | $0 | $789,000 | $2.5M |
| Net income | -$5.5M | $2.6M | -$6.5M | -$16.3M | -$26.7M | -$124.3M | -$115.3M | $74.1M |
| EPS (diluted) | -$0.15 | $0.04 | -$0.18 | -$0.45 | -$0.74 | -$3.42 | -$3.16 | -$0.27 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$23.6M | -$32.5M | -$47.4M | -$37.6M | -$25.8M |
| Capital expenditure | -$1.3M | -$2.2M | -$8.1M | -$1.9M | -$542,000 |
| Free cash flow | -$24.9M | -$34.7M | -$55.6M | -$39.4M | -$26.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $26.3M | $44.5M | $5,000 | $130,000 | $658,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $24.0M
- Total assets
- $90.0M
- Total liabilities
- $321.1M
- Total debt
- $314.0M
- Net debt
- $290.0M
- Shareholders’ equity
- -$231.2M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 963,383
- Days to cover
- 1.65
- Change vs previous report
- +8.8%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- May 10, 2019
- 1-for-14
- Apr 25, 2017
- 1-for-10
- Aug 7, 2015
- 1-for-50
- May 11, 2006
- 1-for-10